IQ4I Research & Consultancy Published a New Report on Nuclear Medicine/Radiopharmaceuticals Global Market and Estimated to be Worth $8.05 Billion by 2020
The global Nuclear Medicine/Radiopharmaceuticals market is expected to reach $8.05 billion by 2020 as per IQ4I Research & Consultancy Market Report. It is mainly driven by factors such as increased application area on therapeutics, growing awareness and preference for nuclear medicine, ready availability of isotopes, and rise in hybrid imaging. However, factors such as stringent regulatory frameworks, high cost, reduction in reimbursement and short-lived isotopes are hampering the growth.
San Francisco, CA, September 06, 2014 --(PR.com)-- IQ4I Research & Consultancy published a new report on “Nuclear Medicine/ Radiopharmaceuticals Global Market – Forecast To 2020” analyzes and studies the major market drivers & Opportunities, Restraints & Threats in North America, Europe, Asia-Pacific and Rest of the World.
Browse 174 market data tables and 25 figures spread through 284 pages and an exhaustive TOC on “Nuclear Medicine/Radiopharmaceuticals Global Market [End Users (Hospitals, Diagnostic Centers, Academic Research Laboratories & Industries)], Diagnostic Type [SPECT (Technetium (Tc-99m), Gallium (Ga-67), Iodine (I-123), Thallium (Tl-201), Yttrium (Y-90) and Others), PET (Fluorodeoxyglucose (18f-FDG), Rubidium (Rb-82), Gallium (Ga-68) and Others)] & Applications (Oncology, Cardiology, Neurology, Nephrology, and Others)], Therapeutic (Beta-Radiation, Alpha-Radiation and Brachytherapy)] – Forecast to 2020.”
Early buyers will receive 10% customization of your requirements.
The global Nuclear Medicine/Radiopharmaceuticals market is expected to reach $8.05 billion by 2020 as per IQ4I Research & Consultancy Market Report. It is mainly driven by factors such as increased application area especially on therapeutics, growing awareness and preference for nuclear medicine, ready availability of isotopes, and rise in hybrid imaging. However, factors such as stringent regulatory frameworks, high cost, reduction in reimbursement for molecular imaging and short-lived isotopes along with its transportation are restraining the growth of the market.
In 2013, the North America accounted for the largest share of 52.3% in 2013 of the global Nuclear Medicine/Radiopharmaceuticals market. However, RoW region is expected to grow at the highest CAGR by 2020. The highest CAGR is attributed to the increased awareness among physicians and patients, rise in medical expenditure, improved health care infrastructure and rising trend for cyclotron installations in Russia and South America especially Argentina. Brazil, South Africa, and Russia are proved to be the emerging markets in nuclear medicine market. The governments of South Africa and Australia have joined hands with the help of ANSTO, Australia and NTP, South Africa to build a new reactor facility in South Africa.
Cardinal Health, Inc. (U.S.) is the largest player in the Nuclear Medicine/Radiopharmaceuticals market with a share of XX%, followed by Mallinckrodt Plc (Ireland) and Nordion, Inc. (Canada) accounting for XX% and XX% share respectively. The Nuclear Medicine/Radiopharmaceuticals market is consolidated, with major players accounting for more than 80% market share in 2013. Top ten major players are Cardinal Health, Inc. (U.S.), Mallinckrodt Plc (Ireland), Lantheus Medical imaging Inc (U.S.), Nordion Inc (Canada), and Triad Isotopes Inc (U.S.), .), IBA Group (Belgium), Siemens Healthcare (Germany), and GE Healthcare (U.K.). Other significant players are Positron Corporation (U.S.), Northstar Medical Radio isotopes (U.S.), Digirad Corporation (U.S.) and Medical Isotopes Inc (U.S.).
Browse 174 market data tables and 25 figures spread through 284 pages and an exhaustive TOC on “Nuclear Medicine/Radiopharmaceuticals Global Market [End Users (Hospitals, Diagnostic Centers, Academic Research Laboratories & Industries)], Diagnostic Type [SPECT (Technetium (Tc-99m), Gallium (Ga-67), Iodine (I-123), Thallium (Tl-201), Yttrium (Y-90) and Others), PET (Fluorodeoxyglucose (18f-FDG), Rubidium (Rb-82), Gallium (Ga-68) and Others)] & Applications (Oncology, Cardiology, Neurology, Nephrology, and Others)], Therapeutic (Beta-Radiation, Alpha-Radiation and Brachytherapy)] – Forecast to 2020.”
Early buyers will receive 10% customization of your requirements.
The global Nuclear Medicine/Radiopharmaceuticals market is expected to reach $8.05 billion by 2020 as per IQ4I Research & Consultancy Market Report. It is mainly driven by factors such as increased application area especially on therapeutics, growing awareness and preference for nuclear medicine, ready availability of isotopes, and rise in hybrid imaging. However, factors such as stringent regulatory frameworks, high cost, reduction in reimbursement for molecular imaging and short-lived isotopes along with its transportation are restraining the growth of the market.
In 2013, the North America accounted for the largest share of 52.3% in 2013 of the global Nuclear Medicine/Radiopharmaceuticals market. However, RoW region is expected to grow at the highest CAGR by 2020. The highest CAGR is attributed to the increased awareness among physicians and patients, rise in medical expenditure, improved health care infrastructure and rising trend for cyclotron installations in Russia and South America especially Argentina. Brazil, South Africa, and Russia are proved to be the emerging markets in nuclear medicine market. The governments of South Africa and Australia have joined hands with the help of ANSTO, Australia and NTP, South Africa to build a new reactor facility in South Africa.
Cardinal Health, Inc. (U.S.) is the largest player in the Nuclear Medicine/Radiopharmaceuticals market with a share of XX%, followed by Mallinckrodt Plc (Ireland) and Nordion, Inc. (Canada) accounting for XX% and XX% share respectively. The Nuclear Medicine/Radiopharmaceuticals market is consolidated, with major players accounting for more than 80% market share in 2013. Top ten major players are Cardinal Health, Inc. (U.S.), Mallinckrodt Plc (Ireland), Lantheus Medical imaging Inc (U.S.), Nordion Inc (Canada), and Triad Isotopes Inc (U.S.), .), IBA Group (Belgium), Siemens Healthcare (Germany), and GE Healthcare (U.K.). Other significant players are Positron Corporation (U.S.), Northstar Medical Radio isotopes (U.S.), Digirad Corporation (U.S.) and Medical Isotopes Inc (U.S.).
Contact
IQ4I Research & Consultancy Pvt. Ltd.
Satish Birudukota
+91 8060500229
iq4i.com
+919886722024
Satish Birudukota
+91 8060500229
iq4i.com
+919886722024
Contact
Categories